Evommune Inc [EVMN] stock prices are up 12.53% to $18.23 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The EVMN shares have gain 6.48% over the last week, with a monthly amount drifted -1.14%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Evommune Inc [NYSE: EVMN] stock has seen the most recent analyst activity on January 08, 2026, when Raymond James initiated its Strong Buy rating and assigned the stock a price target of $40. Previously, H.C. Wainwright started tracking the stock with Buy rating on January 06, 2026, and set its price target to $35. On December 01, 2025, William Blair initiated with an Outperform rating. Morgan Stanley started tracking the stock assigning an Overweight rating and suggested a price target of $36 on December 01, 2025. Leerink Partners initiated its recommendation with an Outperform and recommended $42 as its price target on December 01, 2025. Evercore ISI started tracking with an Outperform rating for this stock on December 01, 2025, and assigned it a price target of $40. In a note dated December 01, 2025, Cantor Fitzgerald initiated an Overweight rating.
The stock price of Evommune Inc [EVMN] has been fluctuating between $13.89 and $24.03 over the past year. Currently, Wall Street analysts expect the stock to reach $38.6 within the next 12 months. Evommune Inc [NYSE: EVMN] shares were valued at $18.23 at the most recent close of the market. An investor can expect a potential return of 111.74% based on the average EVMN price forecast.
Analyzing the EVMN fundamentals
Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -5.41%, Pretax Profit Margin comes in at -4.53%, and Net Profit Margin reading is -4.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is 0.51 and Total Capital is -0.95. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.27 points at the first support level, and at 16.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.94, and for the 2nd resistance point, it is at 19.65.
Ratios To Look Out For
It’s worth pointing out that Evommune Inc [NYSE:EVMN]’s Current Ratio is 7.76. Also, the Quick Ratio is 7.76, while the Cash Ratio stands at 2.57.
Transactions by insiders
Recent insider trading involved Hopfner Robert Lorne, Director, that happened on Dec 19 ’25 when 1000.0 shares were purchased.
